Xeris Pharmaceuticals ( (XERS) ) has released its Q4 earnings. Here is a breakdown of the information Xeris Pharmaceuticals presented to its investors.
Xeris Biopharma Holdings, Inc. is a rapidly expanding biopharmaceutical company focused on developing and commercializing innovative therapies, with a portfolio that includes treatments for conditions such as endogenous Cushing’s syndrome and severe hypoglycemia.
Xeris Biopharma has reported record revenue for the fourth quarter and full-year 2024, with total revenue reaching $60 million for the quarter and $203 million for the year, marking significant growth compared to the previous year. The company also provided optimistic revenue guidance for 2025, anticipating continued robust growth.
Key financial highlights include a 35% increase in quarterly revenue compared to the previous year, driven by strong performance from Recorlev®, which more than doubled its revenue year-over-year. Gvoke® also saw a 24% increase in revenue, while Keveyis® experienced a decline. The company ended the year with $71 million in cash and achieved positive cash flow in the fourth quarter.
Looking ahead, Xeris Biopharma is projecting total revenue between $255 million and $275 million for 2025, indicating over 30% growth at the midpoint. The company remains focused on maintaining positive Adjusted EBITDA and leveraging its growing revenue and improved margins to drive financial transformation.
Overall, Xeris Biopharma’s management is optimistic about the future, emphasizing their commitment to enhancing value for both patients and shareholders through continued execution of their strategic initiatives.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com